Calcium-channel blockers consistently reduced blood pressure in black patients, while beta-blockers did not significantly differ from placebo (WMD -3.53; 95% CI -7.51 to 0.45).
Systematic Review
Do different antihypertensive drugs reduce blood pressure, morbidity, and mortality in hypertensive black adults?
Antihypertensive drugs differ in their blood pressure-lowering efficacy in black patients, with calcium-channel blockers being consistently effective, but morbidity and mortality outcomes do not differ significantly once blood pressure goals are achieved.
Effect estimate: WMD -3.53 (95% CI -7.51 to 0.45)
BACKGROUND: Hypertension occurs more frequently and is generally more severe in black persons than in white persons, leading to excess morbidity and mortality. PURPOSE: To systematically review the efficacy of different antihypertensive drugs in reducing blood pressure, morbidity, and mortality in hypertensive black adults. DATA SOURCES: The following databases were searched from their inception through November 2003: MEDLINE, EMBASE, LILACS (Literatura Latino-Americana y del Caribe en Ciencias de la Salud), African Index Medicus, and the Cochrane Library. PubMed was also searched from September 2003 through March 2004. Searches were conducted without language restriction. STUDY SELECTION: Randomized, controlled trials of drugs versus placebo (blood pressure outcomes) or drugs versus placebo or other drugs (morbidity and mortality outcomes). DATA EXTRACTION: 2 reviewers independently extracted data. DATA SYNTHESIS: The efficacy of beta-blockers in reducing systolic blood pressure and the efficacy of angiotensin-converting enzyme inhibitors in achieving diastolic blood pressure goals did not significantly differ from that of placebo (weighted mean difference for beta-blockers, -3.53 mm Hg 95% CI, -7.51 to 0.45 mm Hg; relative risk for angiotensin-converting enzyme inhibitors, 1.35 CI, 0.81 to 2.26). In the pooled analyses, other reviewed drugs (calcium-channel blockers, diuretics, central sympatholytics, alpha-blockers, and angiotensin II receptor blockers) were more effective than placebo in reducing blood pressure, but only calcium-channel blockers remained effective in all prespecified subgroups, including patients with a baseline diastolic blood pressure of 110 mm Hg or greater. Main morbidity and mortality outcomes did not differ significantly between treatment groups when drugs were combined to reach blood pressure goals. However, trial results indicated a greater occurrence of diabetes with diuretics and a higher risk for cardiovascular events with drug regimens that included angiotensin-converting enzyme inhibitors. LIMITATIONS: This meta-analysis evaluated the blood pressure lowering-efficacy of monotherapy only. CONCLUSIONS: Drugs differ in their efficacy for reducing blood pressure in black patients, but there is no solid evidence that efficacy for reducing morbidity and mortality outcomes differs once patients achieve the blood pressure goal.
Brewster et al. (Tue,) conducted a systematic review in Hypertension. Antihypertensive drugs vs. Placebo or other antihypertensive drugs was evaluated on Systolic blood pressure reduction (beta-blockers vs placebo) (WMD -3.53, 95% CI -7.51 to 0.45). Calcium-channel blockers consistently reduced blood pressure in black patients, while beta-blockers did not significantly differ from placebo (WMD -3.53; 95% CI -7.51 to 0.45).